Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?

被引：20
|
作者：
Trifiro, Gianluca [1 ]
Crisafulli, Salvatore [1 ]
Ando, Giuseppe [2 ]
Racagni, Giorgio [3 ]
Drago, Filippo [4 ]
机构：
[1] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy
[2] Univ Messina, Dept Clin & Expt Med, Messina, Italy
[3] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy
[4] Univ Catania, Univ Hosp, Clin Pharmacol Unit, Dept Biomed & Biotechnol Sci, Catania, Italy
来源：
DRUG SAFETY | 2020年 / 43卷 / 06期
关键词：
GUIDELINES; ESC;
D O I：
10.1007/s40264-020-00935-2
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：507 / 509
页数：3
相关论文
共 50 条
  • [21] Effect of ACE inhibitors and angiotensin receptor blockers on in-hospital mortality and length of stay in hospitalized COVID-19 patients
    LaClair, Heather J.
    Khosrodad, Nadia
    Sule, Anupam A.
    Koehler, Tracy
    Krishnamoorthy, Geetha
    VASCULAR PHARMACOLOGY, 2021, 141
  • [22] Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab
    Niu, Man Man
    Cao, Yue
    Li, Rui Xue
    Fan, Guo Zhen
    Hu, Peng
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (08) : 1504 - 1504
  • [23] Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
    Hippisley-Cox, Julia
    Young, Duncan
    Coupland, Carol
    Channon, Keith M.
    Tan, Pui San
    Harrison, David A.
    Rowan, Kathryn
    Aveyard, Paul
    Pavord, Ian D.
    Watkinson, Peter J.
    HEART, 2020, 106 (19) : 1503 - 1511
  • [24] A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019)
    Talreja, Hari
    Tan, Jasmine
    Dawes, Matt
    Supershad, Sharen
    Rabindranath, Kannaiyan
    Fisher, James
    Valappil, Sajed
    van der Merwe, Veronica
    Wong, Lisa
    van der Merwe, Walter
    Paton, Julian
    NEW ZEALAND MEDICAL JOURNAL, 2020, 133 (1512) : 85 - 87
  • [25] Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors
    Zhou, Xian
    Zhu, Jingkang
    Xu, Tao
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2020, 42 (07) : 656 - 660
  • [26] Assessing the outcomes of prescribing angiotensin converting enzyme inhibitors and angiotensin receptor blockers for COVID-19 patients
    Mekary, Wissam
    Fares, Souha
    Abdulhai, Farah
    Massoud, Gaelle
    Refaat, Marwan
    Mericskay, Mathias
    Booz, George W.
    Zouein, Fouad A.
    HELIYON, 2023, 9 (09)
  • [27] Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19)
    Wietzikoski Lovato, Evellyn Claudia
    Barboza, Lorena Neris
    Wietzikoski, Samantha
    Vasques de Souza, Amanda Nascimento
    Auth, Pablo Alvarez
    Gasparotto Junior, Arquimedes
    dos Reis Livero, Francislaine Aparecida
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (01) : 115 - 126
  • [28] The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
    Harky, Amer
    Chor, Cheryl Yan Ting
    Nixon, Henry
    Jeilani, Milad
    JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2021, 22 (01)
  • [29] Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors and Coronavirus Disease 2019 (COVID-19)
    Albashir, Ahmed Abdalazim Dafallah
    SOUTHERN MEDICAL JOURNAL, 2021, 114 (01) : 51 - 56
  • [30] Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
    Guo, Junyi
    Huang, Zheng
    Lin, Li
    Lv, Jiagao
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (07):
12345